Form 4: ClearPoint Neuro Director Linda Liau Awarded 12,417 Restricted Stock Units

ClearPoint Neuro, Inc. Director Linda M. Liau was granted 12,417 restricted stock units (RSUs) on May 22, 2025, as part of her compensation.

Summary

• Linda M. Liau, a Director of ClearPoint Neuro, Inc. (CLPT), was granted 12,417 Restricted Stock Units (RSUs) on May 22, 2025.
• Each RSU represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock.
• The RSUs were acquired at a price of $0, which is typical for equity grants.
• Following this transaction, Ms. Liau beneficially owns 12,417 derivative securities (RSUs) directly.
• The RSUs are scheduled to vest on the earlier of (i) the first anniversary of the grant date (May 22, 2026), or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The sentiment is positive as it represents a routine equity grant to a director, which aligns management and board interests with shareholders. It does not indicate any negative operational or financial news, nor does it suggest significant immediate market impact beyond standard compensation practices.

Positives

• The grant of restricted stock units to a director aligns her interests with those of the shareholders, as the value of her compensation is tied to the company's stock performance.
• Equity compensation is a common and effective way to incentivize long-term commitment and performance from board members.

Future Outlook

The vesting schedule for the restricted stock units indicates a future issuance of 12,417 shares of common stock to Director Linda M. Liau upon the satisfaction of the vesting conditions, which will occur by the first anniversary of the grant date or prior to the 2026 annual meeting of stockholders.

Industry Context

The granting of restricted stock units to non-employee directors is a standard practice across various industries, including the medical technology and neuro-navigation sector where ClearPoint Neuro operates. This form of compensation is widely used to attract and retain qualified board members and to align their financial incentives with the long-term performance of the company.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a common practice and aligns with industry standards for corporate governance and executive/director incentive structures.
• While the specific number of units granted varies by company size, industry, and individual director responsibilities, the mechanism of granting equity at a $0 price, with a time-based vesting schedule, is consistent with compensation practices observed in comparable medical device or biotechnology companies.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Linda M. Liau, a director of ClearPoint Neuro, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the value of the RSUs is tied to the company's stock performance. It also represents a potential future dilution of existing shares upon vesting, though this is typically factored into compensation plans.
• Employees: No direct impact mentioned, but it reinforces the company's approach to equity-based incentives for key personnel.

Next Steps

• The 12,417 Restricted Stock Units will vest on the earlier of May 22, 2026, or the day immediately preceding the Company's 2026 annual meeting of stockholders, at which point they will convert into shares of ClearPoint Neuro common stock.

Key Dates

Recommendation

Keywords

ClearPoint Neuro, CLPT, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Form 4, SEC Filing